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We report long-term safety & efficacy of infliximab (IFX)+
methotrexate (MTX) treatment in JRA patients. In an inter-
national, multicenter, randomized, double-blind study,
122 children w/active polyarticular JRA despite prior MTX
therapy received MTX plus a 3-dose induction (wks 0, 2,
6) of IFX 3 mg/kg through wk 44, or placebo (PBO) for 14
wks followed by IFX 6 mg/kg (wks 14, 16, 20, & then q8
wks) through wk 44. Patients completing treatment
through wk 44 were eligible to enter an open-label exten-
sion (OLE) of IFX 3 mg/kg, beginning at wk 52 & contin-
uing q8 wks through wk 196. All patients continued with
concomitant MTX. Physicians could increase or decrease
the IFX dose by ≤1.5 mg/kg/infusion q8 wks, up to 6 mg/
kg or down to 3 mg/kg, based on clinical response. Pri-
mary endpoint was the proportion of patients meeting
ACR-Pedi-30, defined as improvement of ≥30% in ≥3 of 6
core variables, & ≤1 of the remaining variables worsened
by >30%. Remission was defined as 0 joints with active
arthritis, normal ESR, & physician's global assessment ≤10
mm on a 10-cm visual analog scale. 78/122(63.9%) chil-
dren entered the OLE. The mean(SD) IFX dose at wk 196
was 4.4(1.6)mg/kg. IFX was well-tolerated;14.1% of
patients discontinued due to adverse events (AE) from
wks 52–204. The distribution/types of AE were similar to
those in the first 52 wks & no new safety issues were
reported. Among the 36 study patients by wk 204, ACR-
Pedi-30/50/70/90 responses were 91.7%(33/36),
83.3%(30/36), 69.4%(25/36), & 50%(18/36), respec-
tively. 39%(14/36) of patients achieved remission. From
wk 52 through wk 216, 36.6%(26/71) of patients were
positive for IFXantibodies; 57.7%(15/26) of these had an
infusion reaction. Continuous IFX+MTX administered up
to 4 yrs was safe & effective in JRA patients, although
accompanied by a high rate of patient discontinuation,
which included subjects in remission.
from 15th Paediatric Rheumatology European Society (PreS) Congress
London, UK. 14–17 September 2008
Published: 15 September 2008
Pediatric Rheumatology 2008, 6(Suppl 1):S3 doi:10.1186/1546-0096-6-S1-S3
<supplement> <title> <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p> </title> <editor>Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/PDF/1546-0096-6-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.ped-rheum.com/content/6/S1/S3
© 2008 Ruperto et al; licensee BioMed Central Ltd. 
